Symposium on antimicrobial agents--Part XII. Vancomycin.
about
Red man syndromePruritus: a useful sign for predicting the haemodynamic changes that occur following administration of vancomycinApproaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics.Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.Use of anti-infective agents during lactation: Part 1--Beta-lactam antibiotics, vancomycin, quinupristin-dalfopristin, and linezolid.Population pharmacokinetic analysis of vancomycin in patients with hematological malignanciesThe intestinal microbiota are necessary for stressor-induced enhancement of splenic macrophage microbicidal activityVancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltrationVancomycin and home health care.Development and validation of an HPLC method for the determination of vancomycin in human plasma and its comparison with an immunoassay (PETINIA).Medication-related complications in the trauma patient.An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in iran.Vancomycin resistance: are there better glycopeptides coming?Nonallergic drug hypersensitivity reactions.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Evaluation of a Pharmacist-Directed Vancomycin Dosing and Monitoring Pilot Program at a Tertiary Academic Medical Center.Comparative in vitro efficacies of various catheter lock solutions.Fluctuations in vancomycin CNS tissue concentrations following intermittent and continuous infusions in the rat.Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.Assessment of vancomycin use in chronic haemodialysis patients: room for improvement.A Rapid and Simple HPLC Method for Therapeutic Monitoring of Vancomycin.Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.
P2860
Q21195101-3BF98903-98AC-4443-87B9-27106DD223DEQ24801272-69C13AF4-241A-49E1-A6D6-4B28210A75EBQ33304458-10AFC70A-D2B5-4D30-97D4-F68E74C46B93Q33836490-CB189153-F555-441D-85AB-91816B341C7FQ34129829-978706BE-153F-4966-B5AC-B8EB689E775CQ34228227-E488CE60-DEB1-4EA5-953B-DECFBB591DA1Q35785384-7AC258A7-B9A0-4C20-89D0-7B71806CE834Q35826283-D0035D4D-8EA2-4311-86FB-2825388C5952Q36006700-BB37D094-1D6E-4A83-8513-01CA5BA01B06Q36595204-EE4D4F44-26DB-4958-B821-A8A0F3860463Q37121344-6AC14292-56DC-401C-ACC2-E4845B530CB6Q37246390-1E358A07-1567-440A-BD09-4720B2073BC8Q37268167-60D42418-FAAD-4F32-8AA1-F4F4C38F9942Q37340562-CC9A2826-0CA0-49F4-B3B3-1EA1E0BD7D2BQ38029476-7FB46788-3927-48FE-873E-387A364CB29BQ38258649-703EB8D4-DD7C-4CF4-9506-BF2F8C73C547Q38492826-4E82B481-0208-4BBC-8163-CFAF6DEC1621Q42424787-2FE4E56E-F052-44CD-ABDD-F818B5FFCC06Q44895276-6414FD4D-8572-42DA-9655-03C7194DD7D8Q45010478-32584F26-2A74-4DE0-B801-56BA421369E3Q46530255-26F80F3B-B476-4A9C-8153-2B3410CA761FQ47605331-575CD4AA-0FDA-4E9F-BA03-DC6A3B4317A9Q51506580-84BA085C-3DB0-42EB-8415-17B539328E01
P2860
Symposium on antimicrobial agents--Part XII. Vancomycin.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Symposium on antimicrobial agents--Part XII. Vancomycin.
@ast
Symposium on antimicrobial agents--Part XII. Vancomycin.
@en
type
label
Symposium on antimicrobial agents--Part XII. Vancomycin.
@ast
Symposium on antimicrobial agents--Part XII. Vancomycin.
@en
prefLabel
Symposium on antimicrobial agents--Part XII. Vancomycin.
@ast
Symposium on antimicrobial agents--Part XII. Vancomycin.
@en
P356
P1476
Symposium on antimicrobial agents--Part XII. Vancomycin.
@en
P2093
P304
P356
10.4065/74.9.928
P407
P577
1999-09-01T00:00:00Z